Summary

for males ages 50 years and up (full criteria)
at UCSF
study started
estimated completion:
Joshua Woolley (ucsf)

Description

Summary

The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).

Details

This study is an open-label mixed-methods pilot study of an individual oral psilocybin drug session combined with ten sessions of an evidence-based, manualized brief group psychotherapy for existential distress in palliative care patients.

Keywords

Distress Depression Grief HIV/AIDS Demoralization Psilocybin Group therapy N,N-Dimethyltryptamine Modified brief Supportive Expressive Group Therapy

Eligibility

For males ages 50 years and up

Inclusion Criterion:

  • Older gay-identified men who are long-term AIDS survivors and suffer from moderate-to-severe demoralization.

Exclusion Criteria:

  • A physical, neurological or cognitive condition that makes participating in the study unsafe or unfeasible.
  • Regular psychotropic medication use.
  • Personal or family history of serious mental illness.
  • Severe depression requiring immediate standard-of-care treatment.
  • Exclusion by the clinical judgment of the study investigators.

Location

  • University of California, San Francisco
    San Francisco California 94143 United States

Lead Scientist

  • Joshua Woolley (ucsf)
    Dr. Woolley has been studying the underpinnings of social deficits in schizophrenia and has examined how oxytocin might be a useful treatment for these social deficits. People with schizophrenia often have functionally significant social cognitive deficits, and there are currently no available pharmacological treatments that target these deficits.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Joshua Woolley
ID
NCT02950467
Phase
Phase 1
Study Type
Interventional
Last Updated